Literature DB >> 31808044

Definition and diagnosis of aggressive pituitary tumors.

Leandro Kasuki1,2,3, Gérald Raverot4,5,6,7.   

Abstract

Pituitary adenomas are considered benign tumors, but approximately 10% of them can have an aggressive behavior and more rarely (0.2%) can present metastasis, being classified as pituitary carcinomas. Aggressive adenomas are generally large and invasive tumors that present unusually rapid growth and/or that grow irrespective of conventional treatment with surgery, medical therapy and radiotherapy. Nevertheless, large tumors, as well as invasive tumors are not always aggressive, with this definition being possible only after clinical follow-up of these tumors, with growth rate and response to therapies being key points to its diagnosis. The correct identification and diagnosis of aggressive adenomas is of great importance as they are associated with great morbidity and increased mortality.

Entities:  

Keywords:  Aggressive tumors; Invasive tumors; Pituitary adenomas; Pituitary carcinoma

Year:  2020        PMID: 31808044     DOI: 10.1007/s11154-019-09531-x

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  15 in total

Review 1.  Diagnosis and treatment of refractory pituitary adenomas: a narrative review.

Authors:  Xiaohai Liu; Congxin Dai; Ming Feng; Mingchu Li; Ge Chen; Renzhi Wang
Journal:  Gland Surg       Date:  2021-04

2.  MicroRNA-30d target TIMP3 induces pituitary tumor cell growth and invasion.

Authors:  Bowen Sun; Congxin Dai; Shangfeng Zhao; Hao Dong; Haocheng Liu; Yong Li; Renzhi Wang; Jun Kang
Journal:  Gland Surg       Date:  2021-12

Review 3.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

4.  Complete Response of a Patient With a Mismatch Repair Deficient Aggressive Pituitary Adenoma to Immune Checkpoint Inhibitor Therapy: A Case Report.

Authors:  Sanjit Shah; Saima Manzoor; Yehudit Rothman; Matthew Hagen; Luke Pater; Karl Golnik; Abdelkader Mahammedi; Andrew L Lin; Ruchi Bhabhra; Jonathan A Forbes; Soma Sengupta
Journal:  Neurosurgery       Date:  2022-05-13       Impact factor: 5.315

5.  High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors.

Authors:  Wenxiu Zhao; Xiaobin Jiang; Karrin Weisenthal; Jun Ma; Erin M Botticelli; Yunli Zhou; E Tessa Hedley-Whyte; Baiyao Wang; Brooke Swearingen; Roy J Soberman; Anne Klibanski; Xun Zhang
Journal:  Front Oncol       Date:  2022-05-13       Impact factor: 5.738

6.  Identification and Verification of SLC27A1, PTBP1 and EIF5A With Significantly Altered Expression in Aggressive Pituitary Adenomas.

Authors:  Jianhua Cheng; Ruya Sun; Ding Nie; Bin Li; Song Bai Gui; Chu Zhong Li; Ya Zhuo Zhang; Peng Zhao
Journal:  Front Surg       Date:  2022-06-21

Review 7.  Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly.

Authors:  Giovanni Tulipano; Andrea Giustina
Journal:  Rev Endocr Metab Disord       Date:  2021-04-05       Impact factor: 6.514

8.  Plurihormonal PIT-1-Positive Pituitary Adenomas: A Systematic Review and Single-Center Series.

Authors:  John P Andrews; Rushikesh S Joshi; Matheus P Pereira; Taemin Oh; Alexander F Haddad; Kaitlyn M Pereira; Robert C Osorio; Kevin C Donohue; Zain Peeran; Sweta Sudhir; Saket Jain; Angad Beniwal; Ashley S Chopra; Narpal S Sandhu; Tarik Tihan; Lewis Blevins; Manish K Aghi
Journal:  World Neurosurg       Date:  2021-04-20       Impact factor: 2.210

9.  Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?

Authors:  Ken Ho; Maria Fleseriu; Ursula Kaiser; Roberto Salvatori; Thierry Brue; M Beatriz Lopes; Pamela Kunz; Mark Molitch; Sally A Camper; Mônica Gadelha; Luis V Syro; Edward Laws; Martin Reincke; Hiroshi Nishioka; Ashley Grossman; Ariel Barkan; Felipe Casanueva; John Wass; Adam Mamelak; Laurence Katznelson; Aart J van der Lely; Sally Radovick; Martin Bidlingmaier; Margaret Boguszewski; Jens Bollerslev; Andrew R Hoffman; Nelson Oyesiku; Gerald Raverot; Anat Ben-Shlomo; Rob Fowkes; Ilan Shimon; Hidenori Fukuoka; Alberto M Pereira; Yona Greenman; Anthony P Heaney; Mark Gurnell; Gudmundur Johannsson; Robert Y Osamura; Michael Buchfelder; Maria Chiara Zatelli; Marta Korbonits; Philippe Chanson; Nienke Biermasz; David R Clemmons; Niki Karavitaki; Marcello D Bronstein; Peter Trainer; Shlomo Melmed
Journal:  J Endocr Soc       Date:  2021-02-09

Review 10.  The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.

Authors:  Congxin Dai; Siyu Liang; Bowen Sun; Jun Kang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-11       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.